Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBITDA (2020 - 2025)

Biofrontera (BFRI) has 6 years of EBITDA data on record, last reported at -$6.3 million in Q3 2025.

  • For Q3 2025, EBITDA fell 26.57% year-over-year to -$6.3 million; the TTM value through Sep 2025 reached -$17.6 million, up 9.01%, while the annual FY2024 figure was -$17.2 million, 24.11% up from the prior year.
  • EBITDA reached -$6.3 million in Q3 2025 per BFRI's latest filing, down from -$5.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.7 million in Q4 2024 and bottomed at -$16.1 million in Q3 2021.
  • Average EBITDA over 5 years is -$5.2 million, with a median of -$5.0 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 908.51% in 2021, then soared 77.4% in 2022.
  • A 5-year view of EBITDA shows it stood at -$1.9 million in 2021, then plummeted by 196.41% to -$5.6 million in 2022, then soared by 31.23% to -$3.9 million in 2023, then surged by 55.71% to -$1.7 million in 2024, then tumbled by 266.71% to -$6.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$6.3 million in Q3 2025, -$5.1 million in Q2 2025, and -$4.5 million in Q1 2025.